AbbVie says FDA approves Skyrizi for ulcerative colitis

AbbVie said that the heavily-advertised drug was now approved for four conditions across different so-called “immune-mediated” inflammatory diseases.

Previous post Trump Media shares continue to drop, as SEC move threatens to ding shareholders
Next post Japan’s exports rise for sixth straight month, thanks to cars and chip equipment